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Purpose: Toxicity caused by acetaminophen and its toxic mechanisms in the liver 
have been widely studied, including effects involving metabolism and oxidative 
stress. However, its adverse effects on heart have not been sufficiently investigated. 
This study evaluated the cardiac influence and molecular events occurring within the 
myocardium in rats treated with a dose of acetaminophen large enough to induce 
conventional liver damage. Materials and Methods: Male rats were orally adminis-
tered a single dose of acetaminophen at 1,000 mg/kg-body weight, and subsequently 
examined for conventional toxicological parameters and for gene expression altera-
tions to both the heart and liver 24 hours after administration. Results: Following 
treatment, serum biochemical parameters including aspartate aminotransferase and 
alanine aminotransferase were elevated. Histopathological alterations of necrosis 
were observed in the liver, but not in the heart. However, alterations in gene expres-
sion were observed in both the liver and heart 24 hours after dosing. Transcriptional 
profiling revealed that acetaminophen changed the expression of genes implicated in 
oxidative stress, inflammatory processes, and apoptosis in the heart as well as in the 
liver. The numbers of up-regulated and down-regulated genes in the heart were 271 
and 81, respectively, based on a two-fold criterion. Conclusion: The induced expres-
sion of genes implicated in oxidative stress and inflammatory processes in the myo-
cardium reflects molecular levels of injury caused by acetaminophen (APAP), which 
could not be identified by conventional histopathology.   
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INTRODUCTION
Acetaminophen (APAP, Tylenol®, also known as paracetamol, N-acetyl-p-amino-
phenol) has analgesic and antipyretic properties and is considered safe in therapeu-
tic doses. However, overdose of APAP can lead to severe liver injury in both hu-
mans and experimental animals. Investigations into the mechanisms underlying 
APAP toxicity have revealed metabolic conversion of APAP to a highly reactive in-
termediate, N-acetyl-p-benzoquinonimine (NAPQI),1 by cytochrome p450s, which Effects of Acetaminophen on Cardiac Gene Expression in Rats
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determine whether alterations that occur in heart tissue dif-
fer from those known to occur in the liver following adminis-
tration of a toxic dose of acetaminophen. Deregulation of nor-
mal gene expression by APAP may be indicative of potential 
adverse effects in the absence of the occurrence of overt tox-
icity. For this study, microarray technology was used for heart 
gene profiling as it provides a rapid and efficient method for 
large-scale profiling of gene expression changes. 
MATERIALS AND METHODS
　　　
Chemicals and animals
APAP, Tween 80, and carboxymethyl cellulose (CMC) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
APAP was dissolved in a 0.5% (w/v) CMC solution contain-
ing 0.1% Tween 80. Male Sprague-Dawley rats, 6 weeks of 
age, were obtained from Orient Co. Ltd (Seongnam, Ko-
rea). The animals were acclimatized to laboratory condi-
tions for one week, and maintained on a 12 h light/dark cy-
cle in the animal room at 23±1°C and humidity 50±5%. 
They were provided with food and drinking water ad libi-
tum. APAP was orally administered to the rats as a single 
dose of 1,000 mg/kg. The dose level was set at the maximum 
tolerated dose level, based on clear signs of toxicity with 
little or no lethality.11 The respective vehicle control was ad-
ministered to the non-treated control group through the 
same oral route. 
Serum biochemistry and hematology
Sera were prepared from whole blood obtained from the 
treated group and the non-treated control group at 24 hours 
after APAP treatment. Clinical chemistry analysis was per-
formed using an automated clinical chemistry analyzer (Hit-
achi7180, Hitachi, Japan). Analysis included the total pro-
tein, albumin, blood urea nitrogen (BUN), creatinine, total 
cholesterol, and the activities of marker enzymes such as as-
partate aminotransferase (AST), alanine aminotransferase 
(ALT), γ-glutamyl transpeptidase (γ-GTP), and alkaline 
phosphatase (ALP). Hematology analysis was performed on 
whole blood collected using ethylenediaminetetraacetic acid 
(EDTA) as an anticoagulant. Erythrocyte, platelet, and leu-
kocyte counts, hematocrit and hemoglobin concentrations, 
mean cell volumes (MCV), mean cell hemoglobin (MCH), 
and mean cell hemoglobin concentrations (MCHC) were 
determined using an automated hematology analyzer (He-
maVet850, Drew-Scientific Group, San Diego, CA, USA). 
are abundant enzymes in liver cells. The active NAPQI me-
tabolite can be detoxified by conjugation with glutathione 
(GSH), a non-protein thiol with both oxidant-scavenging 
and redox-regulating capacities. Following overdose with 
APAP, NAPQI may be generated at much higher levels than 
can be detoxified by conjugation with available GSH. As 
cellular pools of GSH become depleted, NAPQI freely binds 
to functional proteins within the cells, leading to hepatotox-
icity. Metabolism of APAP is also accompanied by the for-
mation of reactive oxygen species (ROS), which initiate lipid 
peroxidation. This peroxidation is a critical factor that causes 
destruction and damage to cell membranes and finally leads 
to necrosis or apoptosis of the liver cells.2 
The number of intoxications by APAP is worrisome.3 In 
2006 alone, the American Association of Poison Control 
Centers implicated acetaminophen in nearly 140,000 poi-
soning cases, in which more than 100 patients died.4 Its in-
cidence has been steadily increasing over the past decade, 
and acetaminophen is now the most common cause of 
acute liver failure. 
Toxicity studies of APAP are now expanding to the mo-
lecular level with the use of microarray techniques to depict 
gene expression profiles in the liver. Toxicogenomics is a 
new discipline of molecular toxicology that incorporates 
the emerging technologies of genomics and bioinformatics 
for the quantitation and characterization of changes in gene 
expression in response to exposure to toxicants. Gene ex-
pression profiling in several laboratories has also allowed 
for prediction of subtle injuries to the liver induced by APAP. 
Functional classification of the differentially expressed genes 
identified those associated with stress responses, the cell 
cycle, growth inhibition, cell death, structural components, 
cell signaling, and inflammation.5,6 
However, few studies have been conducted on cardiac 
toxicity induced by APAP. Myocardial damage with suben-
docardial hemorrhage and focal necrosis was reported fol-
lowing an APAP overdose.7,8 Details on the cardiotoxicity 
caused by APAP have never been further investigated, and 
little is known regarding the precise molecular events oc-
curring within the myocardium following APAP insult. Al-
though the cytochrome p450 enzymes are most abundant in 
the liver, some studies on metabolic enzymes in the heart 
have recently indicated the presence of cytchrome p450s,9,10 
so the possibility of metabolic activation of APAP in the 
heart cannot be excluded. 
The objectives of the present study were to identify APAP-
induced alterations in gene expression in the heart and to Seon Mi Jin, et al.
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fymetrix data were extracted, normalized, and summarized 
using the robust multi-average method implemented in the 
Affymetrix Expression Console. Highly expressed genes 
that showed a 2-fold change in expression were selected. 
The results were classified using hierarchical and K-mean 
clustering algorithms implemented in TMEV software 4.0. 
Differentially expressed genes were then classified based on 
their known biological functions using the Database for 
Annotation, Visualization, and Integrated Discovery soft-
ware. Functional classification was based on both Gene on-
tology and KEGG pathway analysis.
 
RESULTS
 
Serum biochemistry, hematology, and histopathology
Clinical observations and neurobehavioral assessment 
showed no treatment-related changes for 24 hours after a 
high dose (1,000 mg/kg-bw) of APAP. Body weight and 
consumption of water and food did not change significantly 
after treatment with APAP. The toxic effects of APAP were 
evaluated by measuring serum levels of tissue-specific en-
zymes and by histopathological examination. In APAP-
treated rats, significant increases in ALT and AST activity 
were noted 24 hours after treatment of APAP. Changes in 
enzyme activity in serum and blood cells after administra-
tion of APAP are shown in Table 1 and 2. Serum levels of 
ALT were 300.80±322.29 IU/L (mean±SD) in the treated 
group (n=5) and 41.00±7.07 IU/L in the controls (n=4). AST 
levels were 702.80±491.11 IU/L in the treated group (n=5) 
and 104.25±11.08 IU/L in the controls (n=4). BUN, an indi-
cator of kidney damage, was also increased to 14.00±2.44 
mg/dL in the treated group; the control group level was 
9.75±0.50 mg/dL. Other parameters of serum biochemistry, 
including total protein, albumin, total cholesterol, creatinine, 
γ-GTP, and ALP were not changed by APAP administration 
(Table 1). Conventional analysis revealed no changes in he-
matological parameters including white blood cells, red 
blood cells, hemoglobin, hematocrit, MCV, MCH, MCHC, 
platelets, segmented neutrophils, lymphocytes, monocytes, 
eosinophils, and basophils (Table 2). 
Histopathological changes observed in livers from APAP-
treated rats consisted of minimal to moderate degrees of cen-
trilobular hepatocellular necrosis and inflammatory cell infil-
tration, which supported the results of serum transaminases. 
The arrows in Fig. 1 indicate the abnormal regions of necro-
sis in liver. However, no histopathological alterations were 
Histopathology
Livers and hearts were removed and prefixed in 10% (v/v) 
neutral buffered formaldehyde for histopathological exami-
nation. The fixed heart and liver tissues were trimmed, dehy-
drated, embedded in paraffin, sectioned, mounted on glass 
slides, stained with hematoxylin and eosin, and examined by 
light microscopy. A histopathologist evaluated all heart and 
liver sections in a blinded fashion and recorded observations.
RNA isolation and gene expression profiling 
Gene expression analyses were performed using Affyme-
trix GeneChip® Rat Gene 1.0 ST oligonucleotide arrays. The 
sample preparation was performed according to the instruc-
tions and recommendations provided by the manufacturer. 
The treated rats that showed definite histopathological ab-
normalities in the liver but not in the heart by conventional 
toxicology were selected for comparison with non-treated 
rats. Small pieces of tissue from three rats were pooled and 
RNA was extracted. In brief, the total RNA was isolated us-
ing RNeasy Mini Kit columns as described by the manu-
facturer (Qiagen, Hilden, Germany). RNA quality was as-
sessed with an Agilent 2100 bioanalyzer using the RNA 
6000 Nano Chip (Agilent Technologies, Amstelveen, The 
Netherlands), and RNA quantity was determined using an 
ND-1000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA). The 260/280 nm ratio of total RNA 
used in the study was 1.8-2.0. For each RNA sample, 300 ng 
of total RNA was converted to double-stranded cDNA, as 
recommended by the manufacturer. Using a random hexam-
er incorporating a T7 promoter, amplified RNA (cRNA) 
was generated from the double-stranded cDNA template 
though an in-vitro transcription reaction and purified with 
the Affymetrix sample cleanup module. The corresponding 
cDNA was regenerated through a random-primed reverse 
transcription using a deoxyribonucleotide triphosphate 
(dNTP) mix containing deoxyuridine triphosphate (dUTP). 
The cDNA was then fragmented by uracil DNA glycosylase 
(UDG) and apurinic/apyrimidinic (AP) endonuclease 1 
(APE 1) restriction endonucleases and end-labeled by ter-
minal transferase reaction incorporating a biotinylated dide-
oxynucleotide. Fragmented end-labeled cDNA was hybrid-
ized to the GeneChip® rat Gene 1.0 ST arrays for 16 hours 
at 45°C and 60 rpm, as described in the Gene Chip Whole 
Transcript Sense Target Labeling Assay Manual (Affyme-
trix). After hybridization, the chips were stained and washed 
in a Genechip Fluidics Station 450 (Affymetrix) and scanned 
with a Genechip Array scanner 3000 7G (Affymetrix). Af-Effects of Acetaminophen on Cardiac Gene Expression in Rats
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Table 1. Changes in Blood Biochemistry after Treatment with Acetaminophen
  Control group Treated group
Number of animals 4 5
Total protein (g/dL)    5.55±0.23   5.72±0.19
Albumin (g/dL)   2.52±0.12   2.58±0.08
BUN (mg/dL)   9.75±0.50   14.00±2.44*
Creatinine (mg/dL)   0.20±0.00   0.26±0.05
AST (IU/L) 104.25±11.08     702.80±491.11*
ALT (IU/L) 41.00±7.07     300.80±322.29*
γ-GTP (U/L)    1.30±2.46   0.66±0.78
ALP (IU/L) 1,027.50±172.22 1,033.20±262.44
Total cholesterol (mg/dL)   92.00±13.03   82.20±11.96
BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; ALP, 
alkaline phosphatase. 
There were four animals in the control group and five in the treated group. Data are expressed as mean±SD. 
*Indicates p<0.05, significantly different by Mann-Whitney's U-test.  
Table 2. Changes in Blood Cell Count after Treatment with Acetaminophen
  Control group Treated group
WBC (10
3/mm
3)   6.64±2.19   5.65±2.57
RBC (10
3/mm
3)   5.84±0.21   6.32±0.73
Hemoglobin (g/dL) 13.03±0.15 13.66±0.61
Hematocrit (%) 32.15±1.07 35.56±4.33
MCV (fL) 55.13±1.85 56.22±1.31
MCH (pg) 22.33±0.60 21.78±1.95
MCHC (g/dL) 40.55±0.90 38.74±3.45
Platelet (10
3/mm
3)   969.00±140.71   949.60±407.71
Segmented neutrophil (%) 28.20±8.12 39.16±7.17
Lymphocyte (%) 66.23±7.68 56.82±7.32
Monocyte (%)   4.83±2.15   3.34±0.63
Eosinophil (%)    0.53±0.22   0.54±0.32
Basophil (%)   0.23±0.10   0.14±0.05
WBC, white blood cells; RBC, red blood cells; MCV, mean cell volumes; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin 
concentrations. 
There were four animals in the control group and five in the treated group. Data are expressed as mean±SD. 
Fig. 1. Histopathology of the liver and heart 24 hours after treatment. Tissue sections were stained with hematoxylin and eosin. Arrows in-
dicate the regions of necrosis in liver. (A) Control liver. (B) Acetaminophen-treated liver. (C) Control heart. (D) Acetaminophen-treated 
heart (original magnification ×200). Histological observation was done in the control (n=4) and treated groups (n=5) and the representa-
tive data are presented. CV, central vein.
A
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of some genes in the heart were significantly higher than 
those in the liver, while other genes showed the opposite. 
A partial list of the genes induced in the heart and their 
expression ratios in the heart and liver is shown in Table 4. 
In the liver, the expression of genes related to inflammation, 
oxidative stress, and apoptosis were induced, as reported 
previously.12,13 Many of the genes induced in the liver were 
also induced in significant levels in the heart. For example, 
CXCL10, a chemokine ligand 10 gene, was up-regulated 
19.2-fold in the heart and 21.6-fold in the liver. Similarly, 
expression of interferon (IFN) regulatory factor 7 (IRF-7) 
was increased 10.1-fold in the heart and 13.8-fold in the liver. 
Heme oxygenase 1 (Hmox1), a well-known molecular bio-
marker of oxidative stress, was increased 6.1-fold in the heart 
and 4.8-fold in the liver. The expression of caspase (Casp) 
enzymes, which are involved in cellular apoptosis, was sig-
nificantly increased both in the heart and the liver. As men-
tioned, the results of conventional toxicity endpoints, includ-
ing serum biochemistry and histopathology, showed some 
observed in the hearts of the APAP-treated rats in the study.
Gene expression profiling 
Using microarrays, the expression levels of more than 20,000 
genes were analyzed in heart and liver tissues. Twenty-four 
hours after treatment with a single dose of 1,000 mg/kg of 
APAP by oral gavage, 271 genes were up-regulated and 81 
genes were down-regulated in the heart, while 551 genes 
were up-regulated and 404 genes were down-regulated in 
the liver, based on a two-fold criterion. 
Of the 271 up-regulated genes in the heart, 150 gene coun-
terparts were also up-regulated in the liver. However, 121 
genes were uniquely up-regulated in the heart, while 401 
genes were up-regulated only in the liver. Among the 81 
genes down-regulated in the heart, 13 genes were also down-
regulated in the liver, while the remaining 68 were uniquely 
down-regulated in the heart. Among the 404 genes down-
regulated in the liver, 391 were uniquely down-regulated in 
the liver and not in the heart (Table 3). The induction levels 
Table 3. Differentially Expressed Genes in the Heart and Liver of Acetaminophen-Treated Rats
Up regulation Down regulation Total
Liver 551 404 955
Heart 271   81 352
Liver and heart 150   13 163
Only in heart 121   68 189
Only in liver 401 391 792
Table 4. Genes Induced in the Heart and Their Expression Ratios after Acetaminophen Treatment
Gene   
  symbol Gene description Gene accession Expression 
ratio in heart
Expression 
ratio in liver
CXCL10  Chemokine (C-X-Cmotif) ligand10  NM_139089  19.18 21.59
CXCL9  Chemokine (C-X-Cmotif) ligand9  NM_145672  12.93 10.14
IRF7  Interferon regulatory factor7  NM_001033691  10.11 13.83
Hmox1  Heme oxygenase (decycling) 1  NM_012580    6.06   4.75
VCAM1  Vascular cell adhesion molecule1  NM_012889    3.78   1.03
IRF1  Interferon regulatory factor1  NM_012591    3.14   4.17
Gsta2  Glutathione-S-transferase, alpha type 2  NM_017013    3.00   1.71
IRF9  Interferon regulatory factor9  NM_001012041    2.98   2.06
Xdh  Xanthine dehydrogenase  NM_017154    2.80   1.35
Casp1  Caspase1  NM_012762    2.78   1.73
Casp12  Caspase12  NM_130422    2.25 19.03
FGF7  Fibroblast growth factor7  NM_022182    2.24   0.85
Lox1  Oxidized low density lipoprotein (lectin-like) receptor1  NM_133306    2.18 10.09
ICAM1  Intercellular adhesion molecule1  NM_012967    2.16   1.36
Casp4  Caspase4, apoptosis-related cysteine peptidase  NM_053736    2.13   4.44
Mgst1  Microsomal glutathioneS-transferase1  NM_134349    2.10   1.17
Edn1  Endothelin1  NM_012548    2.10   2.23
Cdkn1a  Cyclin-dependent kinase inhibitor1A  NM_080782    2.05   3.49Effects of Acetaminophen on Cardiac Gene Expression in Rats
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with neoplasms who undergo cancer therapy are now at a 
substantial risk for deterioration of their cardiovascular 
health. However, the cardiotoxic mechanisms of anticancer 
drugs have not yet been well studied. Oxidative stress seems 
to be the common pathway leading to mitochondrial dam-
age, which then progresses to DNA damage, ATP blockade, 
cellular apoptosis, and finally cardiac dysfunction.14
Many other drugs in addition to anticancer drugs, such as 
APAP, are known to induce oxidative stress and to cause side 
effects during their metabolism in the liver.1,2 However, no 
similar studies have yet been conducted on the cardiotoxicity 
of APAP. Although APAP is considered safe at therapeutic 
doses, it may generate oxidative stress in the heart as well as 
the liver, thereby causing adverse cardiac side effects. In the 
absence of significant toxicity by conventional toxicity end-
points, changes in gene expression are critical for monitoring 
biological effects in the heart, and these changes may predict 
possible cardiotoxicity in response to APAP administration.
In Fig. 1, serious liver damage was observed, based on 
histopathological criteria, when rats were orally treated with 
APAP 1,000 mg/kg-bw, but no histopathological alterations 
were observed in the heart. However, significant alterations 
in gene expression were observed in the heart, as shown in 
Table 4 and 5. Among the induced genes, inflammation-re-
lated genes were conspicuous. 
For example, chemokines are a family of chemotactic cy-
tokines that regulate migration and tissue localization of 
cells that initiate inflammatory responses. The cytokines 
participate in inflammatory leukocyte recruitment, in lym-
phocyte recirculation, and even in cancer metastasis. CXC, 
one subfamily of the chemokines, has two conserved cyste-
ines separated by one amino acid in the N-terminal residue. 
abnormalities only in the liver, but not in the heart (Table 1,   
2 and Fig. 1). However, the expression of many genes related 
to oxidative stress, inflammation, and apoptosis were altered 
in the heart as well as in the liver. This suggested the possi-
bility of intoxication in the heart based on molecular level 
standards. The partial list of genes repressed in the heart 
and their expression ratios in the heart and liver are shown 
in Table 5. In the heart, many cytochrome p450 enzymes 
were repressed. The CYP3A group of cytochrome p450 
proteins, a well-known group of enzymes that metabolize 
drugs, including APAP, was significantly repressed in both 
the heart and liver. Other groups of cytochrome p450s were 
also repressed by APAP. Among the repressed genes in the 
heart, the identity and function of many of the revealed 
genes are still unknown (data not shown).  
DISCUSSION
Drug-induced cardiotoxicity is emerging as an important is-
sue following anticancer treatments. The symptoms encom-
pass a number of heterogeneous side effects including ar-
rhythmias, changes in blood pressure, myocardial ischemia, 
thrombosis, and impairment in myocardial contraction and/
or relaxation. In the past, the risk of heart complications was 
less evident because life span after chemotherapy was too 
short for the cardiovascular effects to be of major concern. 
With the progress in cancer therapy, however, cardiotoxicity 
has now become a pivotal issue. A number of targeted drugs 
in addition to conventional anthracyclines now represent the 
current mainstay of treatment for several forms of cancer, but 
their use is hampered by cardiac side effects. Many patients 
Table 5. Genes Repressed in the Heart and Their Expression Ratios after Acetaminophen Treatment
Gene 
  symbol Gene description Gene accession Expression 
ratio in heart
Expression 
ratio in liver
CYP3A2  Cytochrome P450, family3, subfamily A, polypeptide2 NM_153312  0.32 0.29
CYP4A1  Cytochrome P450, family4, subfamily A, polypeptide1 NM_175837  0.35 0.47
Scn4b  Sodium channel, typeIV, beta  NM_001008880  0.44 0.91
Agtrl1  Angiotensin receptor-like1  NM_031349  0.44 1.05
CYP3A18  Cytochrome P450, 3a18  NM_145782  0.45 0.37
CYP2J4  Cytochrome P450, family2, subfamily J, polypeptide4  NM_023025  0.46 0.30
Nav3  Neuron navigator3  XM_001078354  0.48 1.02
Inha  Inhibin alpha  NM_012590  0.48 0.91
Nr4a1  Nuclear receptor subfamily4, groupA, member1  NM_024388  0.48 2.24
Aspn  Asporin  NM_001014008  0.49 0.36
Nes  Nestin  NM_012987  0.49 1.06
Igh-1a  Immunoglobulin heavy chain1a (serum IgG2a)  BC107452  0.49 0.61Seon Mi Jin, et al.
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in the pathogenesis of cardiovascular disease.21 ICAM-1 pro-
motes adhesion between leucocytes and endothelial cells, al-
lowing for tissue-specific localization of leucocytes for im-
mune and inflammatory responses. Cell-cell recognition, 
leukocyte rolling, and trafficking processes are dependent on 
cell surface ICAM-1 expression.22 ICAM-1 mRNA expres-
sion levels are increased in response to some stimuli, and 
several inflammatory cytokines and hydrogen peroxide can 
stimulate ICAM-1 expression.23 ICAM-1 is also increased in 
the rat myocardium in various models of cardiac ischemia 
reperfusion injury. The oxidative stress and cytokine release 
that occur in the infarcted heart are considered to activate 
NF-κB, while NF-κB activation triggers gene expression of 
adhesion molecules including VCAM-1 and ICAM-1.24 In 
the present study, ICAM-1 was induced by APAP in the heart 
(2.2-fold), but its expression was not altered significantly in 
the liver. The significance of the induction of inflammation-
related genes as a consequence of APAP treatment is very 
difficult to interpret because the functions of CXCLs and 
IRFs are varied and intricate. 
The induced expression of VCAM-1 and ICAM-1 in 
heart tissue reflects molecular levels of inflammation and 
oxidative damage caused by APAP, which were not identi-
fied by conventional histopathological measurements. Some 
cellular stresses, including oxidative stress, were generated 
in the heart by APAP administration, and consequently, the 
inflammation-related genes were induced as a means of 
maintaining homeostasis. Confirmation of this was evident in 
the significant induction of the Hmox1 gene (6.1-fold), which 
is a well-known biomarker of oxidative stress in cells. Previ-
ous in vivo studies showed that oxidative stress in the liver, 
represented by an increased Hmox1, was induced by a high 
dose of APAP.12,13 The up-regulation of Hmox1 by stress-
causing agents could mediate cytoprotection against subse-
quent noxious stimuli, which may be an important physio-
logical process.12 Thus, physiological induction of Hmox1 
may represent a protective response to oxidative stress in-
duced by high doses of APAP. The xanthine dehydrogenase 
gene, which is induced in cells during oxidative stress, was 
also induced by APAP (2.8-fold). 
Based on the induction of these stress genes, oxidative 
stress was evidently generated in the hearts of rats treated 
with APAP. In general, oxidative stress may trigger inflam-
mation and ultimately lead to cellular toxicity through the 
apoptotic process. The imbalance between ROS production 
and antioxidant mechanisms leads to myocyte dysfunction, 
injury, and necrosis. ROS can cause lipid peroxidation, re-
In the CXC subfamily, more than 17 ligands have been iden-
tified.15 The expression of the CXCL10 [chemokine (CXC 
motif) ligand 10] gene was dramatically higher in both the 
hearts and livers of the APAP-treated group (19.2-fold in 
heart, 21.6-fold in liver) than in the control group. CXCL9 
was also significantly induced in the heart (12.9-fold).  
IRFs, implicated as regulators of the IFN gene, represent 
a family with a total of nine members with multiple func-
tions.16,17 IFNs are a family of multi-functional cytokines 
that mediate cellular resistance against viral infection and 
also have diverse functions in immune responses to patho-
gens, immunomodulation, and hematopoietic development. 
Expression of IFNs is regulated by several IRFs. Following 
treatment with APAP, IRF-7 was induced 10.1-fold in the 
heart. IRF-1 and IRF-9 were also induced in the heart (3.1- 
and 3.0-fold, respectively). IRF-1 has been assigned a dual 
role in apoptosis, as it serves both pro- and anti- apoptotic 
functions. In general, IRF-1 activity does not lead to cell 
death. However, under certain physiological and pathologi-
cal conditions, it promotes apoptosis. The induction of Casp1 
by IRF-1 has been shown to be an essential component of 
apoptosis induction.16 Transcription of other members of the 
family of caspases is also induced by IRF-1. Furthermore, 
IRF-1 can act as a mediator of cytokine-induced apoptosis, 
and IRF-1 induction appears to be an important signaling 
event in the initiation of apoptosis by IFN-γ.16,17 Up-regula-
tion of IRF-1 suggests the possibility that apoptotic processes 
might be induced in the rat heart after APAP intoxication. 
Vascular cell adhesion molecule 1 (VCAM-1) is one of 
the endothelial cell adhesion molecules that mediates leu-
kocyte binding and regulates leukocyte migration from the 
blood into tissues.18 VCAM-1 activates reduced nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase 
in endothelial cells for generation of ROS, while these ROS 
activate matrix metalloproteinases (MMPs). Hydrogen per-
oxide from the VCAM-1 signaling pathway also modulates 
actin restructuring, causing cytoskeletal changes in endotheli-
al cells. Degradation of the extracellular matrix by MMPs 
and changes to endothelial cell actin structure are required 
for VCAM-1 dependent lymphocyte migration. Previous 
studies have reported that VCAM-1 expression was induced 
in endothelial cells under inflammatory conditions.18,19 In 
addition, VCAM-1 was increased in the liver by APAP, re-
flecting the vascular damage it produced.20 In the present 
study, the heart VCAM-1 gene was induced 3.8-fold.  
Increasing interest is now being shown in the roles of in-
tercellular adhesion molecule-1 (ICAM-1), which functions Effects of Acetaminophen on Cardiac Gene Expression in Rats
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calcium may shorten phase 2 of the cardiac action potential, 
providing a negative inotropic effect and decreasing myo-
cardial oxygen and energy consumption. Up-regulation of 
FGF7 may be a protective response to oxidative stress in-
duced by APAP in the heart, and cGMP and nitric oxide   
would be involved in this cytoprotective response. In our 
study, the Nrf2 gene, which is one of the important transcrip-
tion factors for oxidative stress, was not altered by APAP. Al-
though Nrf2 has been known to be one of the important 
transcription factors for oxidative stress or detoxification, it 
is known that Nrf2 induction is not always observed con-
comitantly with the induction of Nrf2-mediated oxidative 
stress related genes. Furthermore, decreased expression of 
Nrf2 gene was reported in the presence of APAP.31 
In contrast to the large numbers of the genes induced by 
APAP in the heart, the number of repressed heart genes was 
relatively small and most of these genes have yet to be identi-
fied. Among those with established identities were many cy-
tochrome p450 genes, including CYP3A, which is known 
to be actively involved in the metabolism of APAP. The ex-
pression ratio was 0.32 in this study. Other groups of cyto-
chrome p450s, such as CYP4A and CYP2J, were also re-
pressed, with ratios of 0.35 and 0.46, respectively. During 
metabolism of APAP, toxic metabolites including NAPQI 
were generated; these metabolites may attack the mRNA 
responsible for translation of metabolic enzymes. Further-
more, toxic metabolites generated by the liver may cause 
adverse effects when they reach the heart. There are also 
other potential roles of liver injury and systemic inflamma-
tion that can have undesirable effects on heart function. 
This was not clarified in this study. 
In summary, liver injury was induced in rats sacrificed 24 
hours after oral administration of 1,000 mg/kg APAP. In 
contrast, heart intoxication was not identified at the same 
dosage level by conventional histopathology. However, the 
induction of many genes related to the processes of oxida-
tive stress, inflammation, and apoptosis was identified in 
the heart using microarray analysis. These results suggest 
that APAP may cause unfavorable pathological changes in 
the heart, and that further studies are needed to identify the 
molecular mechanisms of cardiotoxicity induced by this 
frequently used over-the-counter drug. 
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